AGTC Appoints Michael Goldstein, M.D. As Chief Medical Officer

GAINESVILLE, Fla., and CAMBRIDGE, Mass., Nov. 17, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (NASDAQ:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, today announced the appointment of Michael Goldstein, M.D., M.B.A. as Chief Medical Officer (CMO) effective as of December 1, 2016. Dr. Goldstein will be responsible for leading the company's clinical trials, providing medical oversight, and contributing to the overall strategic direction of the company. AGTC's current Vice President and CMO, Jeffrey D. Chulay, M.D., DTM&H, will remain with the company as Executive Director of Clinical Strategy.  

"Mike's extensive clinical background in ophthalmology, along with his experience serving as CMO of a publicly traded company, will further strengthen our management team as we advance our lead gene therapy development programs," said Sue Washer, President and CEO of AGTC. "We recognize Jeff's substantial contributions throughout his ten years with AGTC and look forward to his ongoing contribution in his new role. We are extremely fortunate that the company will be able to continue to benefit from Jeff's experience in gene therapy and his strong relationships with key opinion leaders to assure a smooth transition as Mike assumes the CMO position."

Prior to joining AGTC, Dr. Goldstein held multiple roles of increasing responsibility with Eleven Biotherapeutics, including as Chief Medical Officer and Vice President of Clinical Research, where he worked with Eleven's team to bring a novel treatment for dry eye disease from early research to a completed pivotal trial. Since 2002 he has served as Co-Director of Cornea and External Disease Service and Assistant Professor of Ophthalmology at the New England Eye Center. Previously, he was Director of Refractive Surgery Service and Assistant Professor of Ophthalmology at the University of Florida College of Medicine. Dr. Goldstein has published extensively and is a reviewer for multiple ophthalmology scientific journals. He holds an M.D. from Northwestern University Medical School, an M.B.A. from Northwestern University's J.L. Kellogg Graduate School of Management and a B.A. in Political Economy from Williams College.

If you liked this article you might like

These 5 Stocks Are Ready to Break Out

Applied Genetic Technologies Is an Attractive Acquisition Target for Allergan or Biogen

Here's Why Applied Genetic (AGTC) Stock Is Plummeting Today

5 Best-Positioned Biotech Stocks on Brexit Volatility

4 Stocks Spiking on Big Volume